Rifaximin-mediated changes to the epithelial cell proteome: 2-D gel analysis

PLoS One. 2013 Jul 26;8(7):e68550. doi: 10.1371/journal.pone.0068550. Print 2013.

Abstract

Rifaximin is a semi-synthetic rifamycin derivative that is used to treat different conditions including bacterial diarrhea and hepatic encephalopathy. Rifaximin is of particular interest because it is poorly adsorbed in the intestines and has minimal effect on colonic microflora. We previously demonstrated that rifaximin affected epithelial cell physiology by altering infectivity by enteric pathogens and baseline inflammation suggesting that rifaximin conferred cytoprotection against colonization and infection. Effects of rifaximin on epithelial cells were further examined by comparing the protein expression profile of cells pretreated with rifaximin, rifampin (control antibiotic), or media (untreated). Two-dimensional (2-D) gel electrophoresis identified 36 protein spots that were up- or down-regulated by over 1.7-fold in rifaximin treated cells compared to controls. 15 of these spots were down-regulated, including annexin A5, intestinal-type alkaline phosphatase, histone H4, and histone-binding protein RbbP4. 21 spots were up-regulated, including heat shock protein (HSP) 90α and fascin. Many of the identified proteins are associated with cell structure and cytoskeleton, transcription and translation, and cellular metabolism. These data suggested that in addition to its antimicrobial properties, rifaximin may alter host cell physiology that provides cytoprotective effects against bacterial pathogens.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line
  • Down-Regulation / drug effects
  • Electrophoresis, Gel, Two-Dimensional*
  • Epithelial Cells / drug effects
  • Epithelial Cells / metabolism*
  • Humans
  • Peptides / metabolism
  • Proteome / metabolism*
  • Proteomics
  • Rifamycins / pharmacology*
  • Rifaximin
  • Up-Regulation / drug effects

Substances

  • Peptides
  • Proteome
  • Rifamycins
  • Rifaximin

Grants and funding

This work was funded by a commercial source, Salix Pharmaceuticals. Salix Pharmaceuticals had no role in the design of the experiments, interpretation of the data, writing of the manuscript, nor in deciding whether the data should be published. In the past, HLD has received honoraria for speaking and consulting fees from Salix Pharamaceuticals but in the context of the study described, none of the authors were paid a consultant fee nor were any patents relating to this work filed. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.